REPL vs. CCCC, TCRX, OCGN, SLDB, LXEO, AURA, TRML, AVXL, VYGR, and EDIT
Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include C4 Therapeutics (CCCC), TScan Therapeutics (TCRX), Ocugen (OCGN), Solid Biosciences (SLDB), Lexeo Therapeutics (LXEO), Aura Biosciences (AURA), Tourmaline Bio (TRML), Anavex Life Sciences (AVXL), Voyager Therapeutics (VYGR), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Replimune Group (NASDAQ:REPL) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Replimune Group received 127 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.54% of users gave Replimune Group an outperform vote while only 37.88% of users gave C4 Therapeutics an outperform vote.
Replimune Group has a net margin of 0.00% compared to C4 Therapeutics' net margin of -629.24%. Replimune Group's return on equity of -42.94% beat C4 Therapeutics' return on equity.
Replimune Group currently has a consensus price target of $37.67, indicating a potential upside of 460.52%. C4 Therapeutics has a consensus price target of $10.11, indicating a potential upside of 69.37%. Given Replimune Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Replimune Group is more favorable than C4 Therapeutics.
92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 20.6% of Replimune Group shares are owned by insiders. Comparatively, 8.0% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, C4 Therapeutics had 11 more articles in the media than Replimune Group. MarketBeat recorded 15 mentions for C4 Therapeutics and 4 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.81 beat C4 Therapeutics' score of 0.76 indicating that Replimune Group is being referred to more favorably in the media.
C4 Therapeutics has higher revenue and earnings than Replimune Group. C4 Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
Replimune Group has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the S&P 500.
Summary
Replimune Group beats C4 Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Replimune Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Replimune Group Competitors List
Related Companies and Tools
